Tumor Markers for Potentially Predicting Outcome of Anti-angiogenesis Therapy


The National Cancer Institute is interested in collaborative research to co-develop, evaluate, or commercialize  p53, tumor  apoptosis, and HER2 as markers for anti-angiogenesis therapy.

Researchers at the National Cancer Institute have identified tumor cell apoptosis, p53, and HER2 as having potential predictive significance for treatment outcome in breast cancer patients who received anti-angiogenesis therapy in combination with chemotherapy. The researchers have developed a quantitative antibody-based testing method for correlating expression of p53 and HER2 and tumor apoptosis with clinical outcome. These markers can be potentially applied to predict which patients should receive anti-angiogenesis therapy plus chemotherapy.



Potential Commercial Applications: Competitive Advantages:
  • A diagnostic kit for predicting benefit of anti-angiogenesis therapy plus chemotherapy in breast cancer patients.
  • A testing service for breast cancer patients.
 
  • The clinical predictive markers p53, HER2 and tumor apoptosis indicators are easily and readily evaluated using the new assay.
  • New assay potentially useful to determine which patients should or should not receive anti-angiogenesis therapy plus chemotherapy for longer survival and progression-free survival in patients with breast cancer.
  • A large, randomized follow-up study will be planned by the inventors and potential collaborators.


Development Stage:
Pre-clinical (in vivo)

Inventors:

Sherry Yang (NCI)  ➽ more inventions...

Seth Steinberg (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Application No. 14/002,455
Foreign Filed Application No. PCT/US2012/027283

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-096-2011
Updated: Sep 8, 2016